INmune Bio Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
1.770
+0.080 (4.73%)
At close: Jul 30, 2026, 4:00 PM EDT
1.740
-0.030 (-1.69%)
After-hours: Jul 30, 2026, 5:24 PM EDT
INmune Bio Revenue
In the year 2025, INmune Bio had annual revenue of $50.00K with 257.14% growth.
Revenue (ttm)
$50.00K
Revenue Growth
+257.14%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
21
Market Cap
47.06M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 50.00K | 36.00K | 257.14% |
| Dec 31, 2024 | 14.00K | -141.00K | -90.97% |
| Dec 31, 2023 | 155.00K | -219.00K | -58.56% |
| Dec 31, 2022 | 374.00K | 193.00K | 106.63% |
| Dec 31, 2021 | 181.00K | 170.00K | 1,545.45% |
| Dec 31, 2020 | 11.00K | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Metagenomi Therapeutics | 22.33M |
| BeyondSpring | 1.88M |
| RenovoRx | 1.49M |
| Seres Therapeutics | 1.15M |
| Mereo BioPharma Group | 500.00K |
| aTyr Pharma | 190.00K |
| Impact BioMedical | 39.00K |
INMB News
- 11 hours ago - INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform - GlobeNewsWire
- 10 days ago - INmune Bio processes first umbilical cord tissue at CGT Catapult - TheFly
- 10 days ago - INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform - GlobeNewsWire
- 15 days ago - INmune Bio's XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study - GlobeNewsWire
- 21 days ago - INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer's Disease at AAIC - GlobeNewsWire
- 4 weeks ago - INmune Bio advances CORDStrom platform patent application in the U.S. - TheFly
- 4 weeks ago - INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion - GlobeNewsWire
- 5 weeks ago - INmune Bio receives MHRA approval for Ebstrocel pediatric investigation plan - TheFly